Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. Wang ES, Montesinos P, Foran J, Erba H, et al. J Clin Oncol 2025;43:3381-3390.

Read + Share

Amedeo Smart

Independent Medical Education

Wang ES, Montesinos P, Foran J, Erba H, et al. Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. J Clin Oncol 2025;43:3381-3390.
PMID: 40997296